Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.

• Status: Withdrawn
• Trial end date: 1969-12-31

Summary

This is a safety and efficacy study of add on therapy with seletracetam in patients experiencing refractory epilepsy.

• Phase: Phase 3

Details

• Lead Sponsor: UCB Pharma